BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Icahn Sues Amylin Pharmaceuticals, Inc. (AMLN) in Shake-up Try


4/9/2012 12:35:45 PM

NEW YORK, April 9, 2012 /PRNewswire/ -- Carl C. Icahn today issued the following statement regarding Amylin Pharmaceuticals, Inc.:

The revelation of the Bristol-Myers bid, as well as the Board's failure to disclose it and its subsequent issuance of 10% of the company at $15.62 per share on March 8th and its issuance of options to executive officers at $16.02 per share on March 6th (including 300,000 shares to President, CEO and Board member Daniel Bradbury), constitutes a dramatic change in circumstances requiring the Board to permit shareholders another opportunity to nominate directors and make proposals at the 2012 annual meeting of shareholders. Therefore, we demanded last week that the Board provide shareholders with a new 10-day periodwithin which to provide notice of nominations and proposals to Amylin. The Board ignored this request.

We therefore filed a complaint in Delaware this morning seeking an extension of the nomination deadline. The complaint alleges that Amylin is a company at a crossroads and that stockholders should be entitled to nominate a new slate of directors committed to pursuing a sale of the company. If successful, we intend to nominate a slate of directors that we hope will be able to focus the Board on being receptive to bids for the company rather than on diluting its owners.

We also delivered to Amylin last week a demand under Section 220 of the Delaware General Corporation Law for copies of Amylin's books and records, so that we may examine the circumstances surrounding the reported Bristol-Myers Squibb proposal and the dilutive stock offering and option grants. These are matters that, in my opinion, shareholders are entitled to fully understand. Amylin is required to respond to this demand by Wednesday. If the company does not do so, we will be in court again. We believe the materials produced in response to this demand may well give rise to another lawsuit against the Board for breaches of its fiduciary duties.

SOURCE Carl C. Icahn



Read at BioSpace.com
Read at Bloomberg
Read at CNBC
Read at Seattle Times
Read at Wall Street Journal
Read at Bradenton Herald
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES